Abstract
Abstract
Background
Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established.
Results
Here, we report a patient with neurofibromatosis type 1 (NF1), medically refractory epilepsy (MRE), and an extensive optic pathway glioma (OPG) who developed dose-dependent seizure control while being treated with selumetinib. Seizure frequency rebounded after dose reduction for cardiac toxicity, then improved, and finally ceased after restarting full dosing, allowing confidence in the cause of improvement.
Conclusion
Selumetinib may have promise in epilepsy management in other children with NF1 or LGG.
Funder
Alex's Lemonade Stand Foundation for Childhood Cancer
Hyundai Hope On Wheels
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Neurofibromatosis Therapeutic Acceleration Pro
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine,Pediatrics, Perinatology and Child Health
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献